_id
6919e3513c536f8df2318026
Ticker
0W4N.LSE
Name
Formycon AG
Exchange
LSE
Address
Fraunhoferstrasse 15, Planegg, Germany, 82152
Country
UK
Sector
Industry
Currency
EUR
Website
https://www.formycon.com
Description
Formycon AG, a biotechnology company, develops biosimilar drugs in Germany and Switzerland. It provides ranibizumab and aflibercept used in the treatment of neovascular age-related macular degeneration, diabetic macular edema, choroidal neovascularization, proliferative diabetic retinopathy, and macular edema under the Ranivisio, Ongavia, Cimerli, Ranopto, Uptera, and Ravegza brand names, as well as AHZANTIVE, Baiama, and Fovlya brand names. The company's pipeline includes ustekinumab used in the treatment of Crohn's disease, ulcerative colitis, Plaque Psoriasis, and Psoriatic Arthritis under the Otulf, Fymskina, and Sitovab brand names. It is also developing pembrolizumab for the treatment of immuno-oncology diseases, such as advanced melanoma, non-small cell bronchial carcinoma, hodgkin's lymphoma, urothelial carcinomas, tumors in the head and neck area, other tumor diseases; and FYB208 and FYB209 that is indicated for immunology areas. The company was formerly known as Nanohale AG and changed its name to Formycon AG in 2012. Formycon AG was founded in 1999 and is headquartered in Planegg, Germany.
Last Close
25.5
Volume
2277
Current Price
25.25
Change
0.5882352941176415
Last Updated
2025-12-29T14:53:04.087Z
Image
https://logo.clearbit.com/www.formycon.com
Ipo Date
-
Market Cap
209540464
Next Dividend Date
-
Dividend Frequency
-
Dividend Rate
-
Dividend Yield
0
Sentiment
-
Sentiment Sources
0
Current Quarter
2025-06-30
Revenue
8997000
Cost Of Revenue
22437000
Gross Profit
-13440000
Operating Expenses
17951000
Operating Income
-31089000
Interest Expense
259000
Pretax Income
-54885000
Net Income
-54192000
Eps
-3.0678606218022244
Dividends Per Share
-
Shares Outstanding
9343850
Income Tax Expense
693000
EBITDA
-18428000
Operating Margin
-345.54851617205736
Total Other Income Expense Net
-23796000
Cash
27279000
Short Term Investments
6000
Receivables
14890000
Inventories
1173000
Total Current Assets
63049000
Property Plant Equipment
14086000
Total Assets
742562000
Payables
25155000
Short Term Debt
3090000
Long Term Debt
-
Total Liabilities
334228000
Equity
408334000
Bs_currency_symbol
-
Depreciation
13465000
Change In Working Capital
16780000
Cash From Operations
6987000
Capital Expenditures
165000
Cash From Investing
-17255000
Cash From Financing
-4287000
Net Change In Cash
-14555000
Cf_currency_symbol
-
PE
-
PB
1.0923087025572202
ROE
-13.271488536345247
ROA
-7.2979764652648536
FCF
6822000
Fcf Percent
0.7582527509169723
Piotroski FScore
2
Health Score
50
Deep Value Investing Score
5.5
Defensive Investing Score
6.5
Dividend Investing Score
3
Economic Moat Investing Score
6.3
Garp Investing Score
3.5
Growth Investing Score
2.5
Momentum Investing Score
6.5
Net Net Investing Score
4
Quality Investing Score
4
Value Investing Score
4.5
Quarters > 0 > quarter
2025-06-30
Quarters > 0 > income Statement > revenue
8997000
Quarters > 0 > income Statement > cost Of Revenue
22437000
Quarters > 0 > income Statement > gross Profit
-13440000
Quarters > 0 > income Statement > operating Expenses
17951000
Quarters > 0 > income Statement > operating Income
-31089000
Quarters > 0 > income Statement > interest Expense
259000
Quarters > 0 > income Statement > pretax Income
-54885000
Quarters > 0 > income Statement > net Income
-54192000
Quarters > 0 > income Statement > eps
-3.0678606218022244
Quarters > 0 > income Statement > dividends Per Share
-
Quarters > 0 > income Statement > shares Outstanding
17664427
Quarters > 0 > income Statement > income Tax Expense
693000
Quarters > 0 > income Statement > EBITDA
-18428000
Quarters > 0 > income Statement > operating Margin
-345.54851617205736
Quarters > 0 > income Statement > total Other Income Expense Net
-23796000
Quarters > 0 > income Statement > currency_symbol
-
Quarters > 0 > balance Sheet > cash
27279000
Quarters > 0 > balance Sheet > short Term Investments
6000
Quarters > 0 > balance Sheet > receivables
14890000
Quarters > 0 > balance Sheet > inventories
1173000
Quarters > 0 > balance Sheet > total Current Assets
63049000
Quarters > 0 > balance Sheet > property Plant Equipment
14086000
Quarters > 0 > balance Sheet > total Assets
742562000
Quarters > 0 > balance Sheet > payables
25155000
Quarters > 0 > balance Sheet > short Term Debt
3090000
Quarters > 0 > balance Sheet > long Term Debt
-
Quarters > 0 > balance Sheet > total Liabilities
334228000
Quarters > 0 > balance Sheet > equity
408334000
Quarters > 0 > balance Sheet > currency_symbol
-
Quarters > 0 > cash Flow > net Income
-54192000
Quarters > 0 > cash Flow > depreciation
13465000
Quarters > 0 > cash Flow > change In Working Capital
16780000
Quarters > 0 > cash Flow > cash From Operations
6987000
Quarters > 0 > cash Flow > capital Expenditures
165000
Quarters > 0 > cash Flow > cash From Investing
-17255000
Quarters > 0 > cash Flow > cash From Financing
-4287000
Quarters > 0 > cash Flow > net Change In Cash
-14555000
Quarters > 0 > cash Flow > currency_symbol
-
Quarters > 0 > ratios > PE
-3.0678606218022244
Quarters > 0 > ratios > PB
1.0923087025572202
Quarters > 0 > ratios > ROE
-13.271488536345247
Quarters > 0 > ratios > ROA
-7.2979764652648536
Quarters > 0 > ratios > FCF
6822000
Quarters > 0 > ratios > Piotroski FScore
2
Quarters > 0 > ratios > fcf Percent
0.7582527509169723
Quarters > 0 > health Score
50
Quarters > 1 > quarter
2024-12-31
Quarters > 1 > income Statement > revenue
42781000
Quarters > 1 > income Statement > cost Of Revenue
29855000
Quarters > 1 > income Statement > gross Profit
12926000
Quarters > 1 > income Statement > operating Expenses
18486000
Quarters > 1 > income Statement > operating Income
-5297000
Quarters > 1 > income Statement > interest Expense
808000
Quarters > 1 > income Statement > pretax Income
-136554000
Quarters > 1 > income Statement > net Income
-115578000
Quarters > 1 > income Statement > eps
-6.542980420480098
Quarters > 1 > income Statement > dividends Per Share
-
Quarters > 1 > income Statement > shares Outstanding
17664427
Quarters > 1 > income Statement > income Tax Expense
-20976000
Quarters > 1 > income Statement > EBITDA
-97087000
Quarters > 1 > income Statement > operating Margin
-12.381664757719548
Quarters > 1 > income Statement > total Other Income Expense Net
-131257000
Quarters > 1 > income Statement > currency_symbol
-
Quarters > 1 > balance Sheet > cash
41834000
Quarters > 1 > balance Sheet > short Term Investments
6000
Quarters > 1 > balance Sheet > receivables
30709000
Quarters > 1 > balance Sheet > inventories
262000
Quarters > 1 > balance Sheet > total Current Assets
95025000
Quarters > 1 > balance Sheet > property Plant Equipment
14570000
Quarters > 1 > balance Sheet > total Assets
771715000
Quarters > 1 > balance Sheet > payables
17437000
Quarters > 1 > balance Sheet > short Term Debt
2992000
Quarters > 1 > balance Sheet > long Term Debt
-
Quarters > 1 > balance Sheet > total Liabilities
309872000
Quarters > 1 > balance Sheet > equity
461843000
Quarters > 1 > balance Sheet > currency_symbol
-
Quarters > 1 > cash Flow > net Income
-115578000
Quarters > 1 > cash Flow > depreciation
8728000
Quarters > 1 > cash Flow > change In Working Capital
3516000
Quarters > 1 > cash Flow > cash From Operations
7684000
Quarters > 1 > cash Flow > capital Expenditures
563000
Quarters > 1 > cash Flow > cash From Investing
9994000
Quarters > 1 > cash Flow > cash From Financing
-16465000
Quarters > 1 > cash Flow > net Change In Cash
1214000
Quarters > 1 > cash Flow > currency_symbol
-
Quarters > 1 > ratios > PE
-6.542980420480098
Quarters > 1 > ratios > PB
0.9657541236957148
Quarters > 1 > ratios > ROE
-25.02538741520387
Quarters > 1 > ratios > ROA
-14.97677251316872
Quarters > 1 > ratios > FCF
7121000
Quarters > 1 > ratios > Piotroski FScore
2
Quarters > 1 > ratios > fcf Percent
0.16645239709216708
Quarters > 1 > health Score
45
Quarters > 2 > quarter
2024-06-30
Quarters > 2 > income Statement > revenue
26893000
Quarters > 2 > income Statement > cost Of Revenue
24985000
Quarters > 2 > income Statement > gross Profit
1908000
Quarters > 2 > income Statement > operating Expenses
19891000
Quarters > 2 > income Statement > operating Income
-17983000
Quarters > 2 > income Statement > interest Expense
299000
Quarters > 2 > income Statement > pretax Income
-22456000
Quarters > 2 > income Statement > net Income
-10094000
Quarters > 2 > income Statement > eps
-0.5839186692809377
Quarters > 2 > income Statement > dividends Per Share
-
Quarters > 2 > income Statement > shares Outstanding
17286654
Quarters > 2 > income Statement > income Tax Expense
2395000
Quarters > 2 > income Statement > EBITDA
-17517000
Quarters > 2 > income Statement > operating Margin
-66.86870189268583
Quarters > 2 > income Statement > total Other Income Expense Net
10284000
Quarters > 2 > income Statement > currency_symbol
-
Quarters > 2 > balance Sheet > cash
40620000
Quarters > 2 > balance Sheet > short Term Investments
6000
Quarters > 2 > balance Sheet > receivables
39360000
Quarters > 2 > balance Sheet > inventories
2124000
Quarters > 2 > balance Sheet > total Current Assets
95881000
Quarters > 2 > balance Sheet > property Plant Equipment
14714000
Quarters > 2 > balance Sheet > total Assets
947781000
Quarters > 2 > balance Sheet > payables
16948000
Quarters > 2 > balance Sheet > short Term Debt
2466000
Quarters > 2 > balance Sheet > long Term Debt
-
Quarters > 2 > balance Sheet > total Liabilities
371479000
Quarters > 2 > balance Sheet > equity
576302000
Quarters > 2 > balance Sheet > currency_symbol
-
Quarters > 2 > cash Flow > net Income
-10094000
Quarters > 2 > cash Flow > depreciation
1079000
Quarters > 2 > cash Flow > change In Working Capital
-15964000
Quarters > 2 > cash Flow > cash From Operations
-30642000
Quarters > 2 > cash Flow > capital Expenditures
982000
Quarters > 2 > cash Flow > cash From Investing
-12629000
Quarters > 2 > cash Flow > cash From Financing
56856000
Quarters > 2 > cash Flow > net Change In Cash
13585000
Quarters > 2 > cash Flow > currency_symbol
-
Quarters > 2 > ratios > PE
-0.5839186692809377
Quarters > 2 > ratios > PB
0.7573945839160718
Quarters > 2 > ratios > ROE
-1.7515122279638105
Quarters > 2 > ratios > ROA
-1.0650139641963703
Quarters > 2 > ratios > FCF
-31624000
Quarters > 2 > ratios > Piotroski FScore
0
Quarters > 2 > ratios > fcf Percent
-1.1759193842263787
Quarters > 2 > health Score
29
Quarters > 3 > quarter
2023-12-31
Quarters > 3 > income Statement > revenue
33907000
Quarters > 3 > income Statement > cost Of Revenue
28238000
Quarters > 3 > income Statement > gross Profit
5669000
Quarters > 3 > income Statement > operating Expenses
12583000
Quarters > 3 > income Statement > operating Income
-6914000
Quarters > 3 > income Statement > interest Expense
50000
Quarters > 3 > income Statement > pretax Income
63845000
Quarters > 3 > income Statement > net Income
73991000
Quarters > 3 > income Statement > eps
4.613257558635245
Quarters > 3 > income Statement > dividends Per Share
-
Quarters > 3 > income Statement > shares Outstanding
16038775
Quarters > 3 > income Statement > income Tax Expense
-3984000
Quarters > 3 > income Statement > EBITDA
64878000
Quarters > 3 > income Statement > operating Margin
-20.391069690624356
Quarters > 3 > income Statement > total Other Income Expense Net
76734000
Quarters > 3 > income Statement > currency_symbol
-
Quarters > 3 > balance Sheet > cash
27035000
Quarters > 3 > balance Sheet > short Term Investments
6000
Quarters > 3 > balance Sheet > receivables
28304000
Quarters > 3 > balance Sheet > inventories
467000
Quarters > 3 > balance Sheet > total Current Assets
67147000
Quarters > 3 > balance Sheet > property Plant Equipment
12327000
Quarters > 3 > balance Sheet > total Assets
890362000
Quarters > 3 > balance Sheet > payables
16319000
Quarters > 3 > balance Sheet > short Term Debt
21671000
Quarters > 3 > balance Sheet > long Term Debt
-
Quarters > 3 > balance Sheet > total Liabilities
387611000
Quarters > 3 > balance Sheet > equity
502751000
Quarters > 3 > balance Sheet > currency_symbol
-
Quarters > 3 > cash Flow > net Income
73991000
Quarters > 3 > cash Flow > depreciation
983000
Quarters > 3 > cash Flow > change In Working Capital
3307000
Quarters > 3 > cash Flow > cash From Operations
-1308000
Quarters > 3 > cash Flow > capital Expenditures
8630000
Quarters > 3 > cash Flow > cash From Investing
-5330000
Quarters > 3 > cash Flow > cash From Financing
-3192000
Quarters > 3 > cash Flow > net Change In Cash
-9830000
Quarters > 3 > cash Flow > currency_symbol
EUR
Quarters > 3 > ratios > PE
4.613257558635245
Quarters > 3 > ratios > PB
0.8055261327177867
Quarters > 3 > ratios > ROE
14.717225823518998
Quarters > 3 > ratios > ROA
8.31021539553575
Quarters > 3 > ratios > FCF
-9938000
Quarters > 3 > ratios > Piotroski FScore
2
Quarters > 3 > ratios > fcf Percent
-0.29309582092193354
Quarters > 3 > health Score
64
Annuals > 0 > quarter
2024-12-31
Annuals > 0 > income Statement > revenue
69674000
Annuals > 0 > income Statement > cost Of Revenue
54840000
Annuals > 0 > income Statement > gross Profit
14834000
Annuals > 0 > income Statement > operating Expenses
38377000
Annuals > 0 > income Statement > operating Income
-23543000
Annuals > 0 > income Statement > interest Expense
1107000
Annuals > 0 > income Statement > pretax Income
-144253000
Annuals > 0 > income Statement > net Income
-125672000
Annuals > 0 > income Statement > eps
-7.184619134062219
Annuals > 0 > income Statement > dividends Per Share
-
Annuals > 0 > income Statement > shares Outstanding
17491811
Annuals > 0 > income Statement > income Tax Expense
-18582000
Annuals > 0 > income Statement > EBITDA
-4099000
Annuals > 0 > income Statement > operating Margin
-33.79022303872319
Annuals > 0 > income Statement > total Other Income Expense Net
-120710000
Annuals > 0 > income Statement > currency_symbol
-
Annuals > 0 > balance Sheet > cash
41834000
Annuals > 0 > balance Sheet > short Term Investments
6000
Annuals > 0 > balance Sheet > receivables
30709000
Annuals > 0 > balance Sheet > inventories
262000
Annuals > 0 > balance Sheet > total Current Assets
95025000
Annuals > 0 > balance Sheet > property Plant Equipment
14570000
Annuals > 0 > balance Sheet > total Assets
771715000
Annuals > 0 > balance Sheet > payables
17437000
Annuals > 0 > balance Sheet > short Term Debt
1496000
Annuals > 0 > balance Sheet > long Term Debt
-
Annuals > 0 > balance Sheet > total Liabilities
309872000
Annuals > 0 > balance Sheet > equity
461843000
Annuals > 0 > balance Sheet > currency_symbol
-
Annuals > 0 > cash Flow > net Income
-125672000
Annuals > 0 > cash Flow > depreciation
139065000
Annuals > 0 > cash Flow > change In Working Capital
-11820000
Annuals > 0 > cash Flow > cash From Operations
-23221000
Annuals > 0 > cash Flow > capital Expenditures
29940000
Annuals > 0 > cash Flow > cash From Investing
-1459000
Annuals > 0 > cash Flow > cash From Financing
39478000
Annuals > 0 > cash Flow > net Change In Cash
14799000
Annuals > 0 > cash Flow > currency_symbol
-
Annuals > 0 > ratios > PE
-7.184619134062219
Annuals > 0 > ratios > PB
0.9657853004159422
Annuals > 0 > ratios > ROE
-27.21097862260552
Annuals > 0 > ratios > ROA
-16.28476834064389
Annuals > 0 > ratios > FCF
-53161000
Annuals > 0 > ratios > Piotroski FScore
1
Annuals > 0 > ratios > fcf Percent
-0.7629962396302782
Annuals > 0 > health Score
30
Annuals > 1 > quarter
2023-12-31
Annuals > 1 > income Statement > revenue
77696000
Annuals > 1 > income Statement > cost Of Revenue
54391000
Annuals > 1 > income Statement > gross Profit
23305000
Annuals > 1 > income Statement > operating Expenses
23674000
Annuals > 1 > income Statement > operating Income
-369000
Annuals > 1 > income Statement > interest Expense
94000
Annuals > 1 > income Statement > pretax Income
79070000
Annuals > 1 > income Statement > net Income
75795000
Annuals > 1 > income Statement > eps
4.722837159291493
Annuals > 1 > income Statement > dividends Per Share
-
Annuals > 1 > income Statement > shares Outstanding
16048616
Annuals > 1 > income Statement > income Tax Expense
3275000
Annuals > 1 > income Statement > EBITDA
81053000
Annuals > 1 > income Statement > operating Margin
-0.474927924217463
Annuals > 1 > income Statement > total Other Income Expense Net
79439000
Annuals > 1 > income Statement > currency_symbol
-
Annuals > 1 > balance Sheet > cash
27035000
Annuals > 1 > balance Sheet > short Term Investments
6000
Annuals > 1 > balance Sheet > receivables
28304000
Annuals > 1 > balance Sheet > inventories
467000
Annuals > 1 > balance Sheet > total Current Assets
67147000
Annuals > 1 > balance Sheet > property Plant Equipment
12327000
Annuals > 1 > balance Sheet > total Assets
890362000
Annuals > 1 > balance Sheet > payables
16319000
Annuals > 1 > balance Sheet > short Term Debt
21671000
Annuals > 1 > balance Sheet > long Term Debt
-
Annuals > 1 > balance Sheet > total Liabilities
387611000
Annuals > 1 > balance Sheet > equity
502751000
Annuals > 1 > balance Sheet > currency_symbol
-
Annuals > 1 > cash Flow > net Income
75795000
Annuals > 1 > cash Flow > depreciation
1887000
Annuals > 1 > cash Flow > change In Working Capital
-12819000
Annuals > 1 > cash Flow > cash From Operations
-9848000
Annuals > 1 > cash Flow > capital Expenditures
1029000
Annuals > 1 > cash Flow > cash From Investing
-17380000
Annuals > 1 > cash Flow > cash From Financing
44443000
Annuals > 1 > cash Flow > net Change In Cash
17215000
Annuals > 1 > cash Flow > currency_symbol
EUR
Annuals > 1 > ratios > PE
4.722837159291493
Annuals > 1 > ratios > PB
0.8140007836881479
Annuals > 1 > ratios > ROE
15.076051564293259
Annuals > 1 > ratios > ROA
8.512829613123651
Annuals > 1 > ratios > FCF
-10877000
Annuals > 1 > ratios > Piotroski FScore
2
Annuals > 1 > ratios > fcf Percent
-0.13999433690280066
Annuals > 1 > health Score
64
Annuals > 2 > quarter
2022-12-31
Annuals > 2 > income Statement > revenue
42497000
Annuals > 2 > income Statement > cost Of Revenue
30425000
Annuals > 2 > income Statement > gross Profit
12072000
Annuals > 2 > income Statement > operating Expenses
29800000
Annuals > 2 > income Statement > operating Income
-17728000
Annuals > 2 > income Statement > interest Expense
143000
Annuals > 2 > income Statement > pretax Income
36596000
Annuals > 2 > income Statement > net Income
35992000
Annuals > 2 > income Statement > eps
2.592360028620254
Annuals > 2 > income Statement > dividends Per Share
-
Annuals > 2 > income Statement > shares Outstanding
13883874
Annuals > 2 > income Statement > income Tax Expense
604000
Annuals > 2 > income Statement > EBITDA
51533000
Annuals > 2 > income Statement > operating Margin
-41.715885827234864
Annuals > 2 > income Statement > total Other Income Expense Net
54324000
Annuals > 2 > income Statement > currency_symbol
-
Annuals > 2 > balance Sheet > cash
9820000
Annuals > 2 > balance Sheet > short Term Investments
-
Annuals > 2 > balance Sheet > receivables
15475000
Annuals > 2 > balance Sheet > inventories
571000
Annuals > 2 > balance Sheet > total Current Assets
30502000
Annuals > 2 > balance Sheet > property Plant Equipment
11516000
Annuals > 2 > balance Sheet > total Assets
853697000
Annuals > 2 > balance Sheet > payables
11318000
Annuals > 2 > balance Sheet > short Term Debt
21715000
Annuals > 2 > balance Sheet > long Term Debt
-
Annuals > 2 > balance Sheet > total Liabilities
497117000
Annuals > 2 > balance Sheet > equity
356580000
Annuals > 2 > balance Sheet > currency_symbol
-
Annuals > 2 > cash Flow > net Income
35992000
Annuals > 2 > cash Flow > depreciation
1862000
Annuals > 2 > cash Flow > change In Working Capital
-3252000
Annuals > 2 > cash Flow > cash From Operations
-18994000
Annuals > 2 > cash Flow > capital Expenditures
26759000
Annuals > 2 > cash Flow > cash From Investing
-37070000
Annuals > 2 > cash Flow > cash From Financing
40855000
Annuals > 2 > cash Flow > net Change In Cash
-15209000
Annuals > 2 > cash Flow > currency_symbol
EUR
Annuals > 2 > ratios > PE
2.592360028620254
Annuals > 2 > ratios > PB
0.992873372034326
Annuals > 2 > ratios > ROE
10.093667620169388
Annuals > 2 > ratios > ROA
4.216015752661659
Annuals > 2 > ratios > FCF
-45753000
Annuals > 2 > ratios > Piotroski FScore
2
Annuals > 2 > ratios > fcf Percent
-1.076617172976916
Annuals > 2 > health Score
50
Annuals > 3 > quarter
2021-12-31
Annuals > 3 > income Statement > revenue
36613000
Annuals > 3 > income Statement > cost Of Revenue
26503000
Annuals > 3 > income Statement > gross Profit
10110000
Annuals > 3 > income Statement > operating Expenses
23938000
Annuals > 3 > income Statement > operating Income
-13828000
Annuals > 3 > income Statement > interest Expense
173000
Annuals > 3 > income Statement > pretax Income
-14207000
Annuals > 3 > income Statement > net Income
-13290000
Annuals > 3 > income Statement > eps
-1.2035166593782518
Annuals > 3 > income Statement > dividends Per Share
-
Annuals > 3 > income Statement > shares Outstanding
11042639
Annuals > 3 > income Statement > income Tax Expense
-917000
Annuals > 3 > income Statement > EBITDA
-12422000
Annuals > 3 > income Statement > operating Margin
-37.76800589954388
Annuals > 3 > income Statement > total Other Income Expense Net
-207000
Annuals > 3 > income Statement > currency_symbol
EUR
Annuals > 3 > balance Sheet > cash
25029000
Annuals > 3 > balance Sheet > short Term Investments
150000
Annuals > 3 > balance Sheet > receivables
11938000
Annuals > 3 > balance Sheet > inventories
209000
Annuals > 3 > balance Sheet > total Current Assets
37942000
Annuals > 3 > balance Sheet > property Plant Equipment
8431000
Annuals > 3 > balance Sheet > total Assets
70715000
Annuals > 3 > balance Sheet > payables
7606000
Annuals > 3 > balance Sheet > short Term Debt
1754000
Annuals > 3 > balance Sheet > long Term Debt
-
Annuals > 3 > balance Sheet > total Liabilities
14824000
Annuals > 3 > balance Sheet > equity
55891000
Annuals > 3 > balance Sheet > currency_symbol
EUR
Annuals > 3 > cash Flow > net Income
-13290000
Annuals > 3 > cash Flow > depreciation
1612000
Annuals > 3 > cash Flow > change In Working Capital
-1745000
Annuals > 3 > cash Flow > cash From Operations
-13541000
Annuals > 3 > cash Flow > capital Expenditures
941000
Annuals > 3 > cash Flow > cash From Investing
-3929000
Annuals > 3 > cash Flow > cash From Financing
491000
Annuals > 3 > cash Flow > net Change In Cash
-16979839
Annuals > 3 > cash Flow > currency_symbol
EUR
Annuals > 3 > ratios > PE
-1.2035166593782518
Annuals > 3 > ratios > PB
5.038150945590524
Annuals > 3 > ratios > ROE
-23.77842586462937
Annuals > 3 > ratios > ROA
-18.79374955808527
Annuals > 3 > ratios > FCF
-14482000
Annuals > 3 > ratios > Piotroski FScore
1
Annuals > 3 > ratios > fcf Percent
-0.39554256684784095
Annuals > 3 > health Score
30
Valuation > metrics > PE
-3.0678606218022244
Valuation > metrics > PB
1.0923087025572202
Valuation > final Score
80
Valuation > verdict
Fair
Profitability > metrics > ROE
-13.271488536345247
Profitability > metrics > ROA
-85.95219591111675
Profitability > metrics > Net Margin
-6.023341113704568
Profitability > final Score
0
Profitability > verdict
Weak
Risk > metrics > Debt Equity
0.8185162146674047
Risk > metrics > Interest Coverage
-120.03474903474904
Risk > final Score
-432
Risk > verdict
High
Liquidity > metrics > Current Ratio
2.2322180916976455
Liquidity > metrics > Quick Ratio
2.1906886174544167
Liquidity > final Score
100
Liquidity > verdict
Great
Prev Valuations > 0
70
Prev Valuations > 1
70
Prev Valuations > 2
90
Prev Profitabilities > 0
0
Prev Profitabilities > 1
0
Prev Profitabilities > 2
89
Prev Risks > 0
22
Prev Risks > 1
-193
Prev Risks > 2
-505
Prev Liquidities > 0
100
Prev Liquidities > 1
100
Prev Liquidities > 2
94
Updated At
2026-01-20T22:59:22.550Z
Earnings History > 0 > period
2025-12-31
Earnings History > 0 > report Date
2026-03-24
Earnings History > 0 > date
2025-12-31
Earnings History > 0 > before After Market
AfterMarket
Earnings History > 0 > currency
-
Earnings History > 0 > eps Actual
-
Earnings History > 0 > eps Estimate
-
Earnings History > 0 > eps Difference
0
Earnings History > 0 > surprise Percent
-
Formycon AG, a biotechnology company, develops biosimilar drugs in Germany and Switzerland. It provides ranibizumab and aflibercept used in the treatment of neovascular age-related macular degeneration, diabetic macular edema, choroidal neovascularization, proliferative diabetic retinopathy, and macular edema under the Ranivisio, Ongavia, Cimerli, Ranopto, Uptera, and Ravegza brand names, as well as AHZANTIVE, Baiama, and Fovlya brand names. The company's pipeline includes ustekinumab used in the treatment of Crohn's disease, ulcerative colitis, Plaque Psoriasis, and Psoriatic Arthritis under the Otulf, Fymskina, and Sitovab brand names. It is also developing pembrolizumab for the treatment of immuno-oncology diseases, such as advanced melanoma, non-small cell bronchial carcinoma, hodgkin's lymphoma, urothelial carcinomas, tumors in the head and neck area, other tumor diseases; and FYB208 and FYB209 that is indicated for immunology areas. The company was formerly known as Nanohale AG and changed its name to Formycon AG in 2012. Formycon AG was founded in 1999 and is headquartered in Planegg, Germany.
Stock Price
€0.00
increase compared to yesterday.
Dividend
Frequency:
Rate:
N/ANext Payout:
N/A(Last Updated 2025-06-30)
Health Score
Price to Book Ratio (P/B)
-
Very Low
Low ≤ 1
High ≥ 3
Return on Equity (ROE)
-
Very Low
Low ≤ 5%
High ≥ 25%
Return on Assets (ROA)
-
Very Low
Low ≤ 2%
High ≥ 10%
Free Cash Flow - Revenue % (FCF)
-
Very High
Low ≤ 5%
High ≥ 15%
Debt to Equity
-
Low
Low ≥ 1
High ≤ 0.3
* Institutions hold a combined 0.00% of the total shares of Formycon AG
* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.
Date
2025-12-31
EPS Estimate
—
Date
—
EPS Actual
—
EPS Estimate
—
EPS Difference
—
Surprise Percent
undefined%
(Last Updated 2025-06-30)
(Last Updated 2025-06-30)
Revenue
€ 0
Cost Of Revenue
€ 0
Gross Profit
€ 0
Operating Expenses
€ 0
Operating Income
€ 0
Interest Expense
€ 0
Pretax Income
€ 0
Net Income
€ 0
Income Tax Expense
€ 0
EBITDA
€ 0
Total Other Income Expense Net
€ 0
Earnings Per Share
0
Dividends Per Share
0
Shares Outstanding
0
Operating Margin
0%
(Last Updated 2025-06-30)
Cash
€ 0
Short Term Investments
€ 0
Receivables
€ 0
Inventories
€ 0
Total Current Assets
€ 0
Property Plant Equipment
€ 0
Total Assets
€ 0
Payables
€ 0
Short Term Debt
€ 0
Long Term Debt
€ 0
Total Liabilities
€ 0
Equity
€ 0
(Last Updated 2025-06-30)
Net Income
€ 0
Depreciation
€ 0
Change In Working Capital
€ 0
Cash From Operations
€ 0
Capital Expenditures
€ 0
Cash From Investing
€ 0
Cash From Financing
€ 0
Net Change In Cash
€ 0
Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.